Serum metabolomics of treatment response in myasthenia gravis.
Patricia SikorskiYaoxiang LiMehar CheemaGil I WolfeLinda L KusnerInmaculada AbanHenry J KaminskiPublished in: PloS one (2023)
We have defined a metabolomic and lipidomic profile that can now undergo validation as a treatment predictive marker for MG patients undergoing corticosteroid therapy. Metabolomic profiles of outcome measures had limited overlap consistent with their assessing distinct aspects of treatment response and supporting unique biological underpinning for each outcome measure. Interindividual variation in prednisone metabolism may be a determinate of how well patients respond to treatment.